Merck and Orna Therapeutics' deal to collaborate on RNA technology was the big pharma deal of August, and could be worth up to $3.5bn in total depending on whether Orna meets certain development, regulatory and sales milestones. (Also see "Merck Buys Into Orna's Circular RNA Platform With Emphasis On Vaccines" - Scrip, 16 August, 2022.)
In the medical device space, United Imaging Healthcare raised a hefty $1.6bn in its IPO and in diagnostics, Bio-Rad fully...